Most of my experience is with small cap biotechs and I can tell you from experience, a reverse split almost always drops the price on those guys as it signals weak cash position with continuing expenses. That said, I believe a reverse split, well-timed, with CDNL will ultimately cause the pps to rise so long as the business is growing. An uplisting for this company could be very good if it occurs the way the 8-k indicates it likely will, after the conditions of the second tranche are met. GLTAL!!!!
News 
Market Data 
Discover 
